Pfizer's Xeljanz down but not out in the EU
This article was originally published in Scrip
Executive Summary
The EU's CHMP has given a second knock-down to Pfizer's JAK inhibitor Xeljanz (tofacitinib citrate), but the firm has vowed to keep boxing on in Europe.